HOME / PUBLICATIONS /

Prognostication in young and old patients with Waldenström's macroglobulinemia: Importance of the international prognostic scoring system and of serum lactate dehydrogenase

Citation:

Kastritis E, Zervas K, Repoussis P, Michali E, Katodrytou E, Zomas A, Simeonidis A, Terpos E, Delimbassi S, Vassou A, et al. Prognostication in young and old patients with Waldenström's macroglobulinemia: Importance of the international prognostic scoring system and of serum lactate dehydrogenase. Clinical Lymphoma and Myeloma [Internet]. 2009;9(1):50 - 52.

Abstract:

We analyzed 232 patients with previously untreated, symptomatic WM, of whom 10% were 50 years of age and 21% were > 75 years of age. Disease features and response to treatment were similar among age groups. Patients > 75 years of age had significantly shorter survival (OS; 53 months vs. 113 months for those > 50-75 years vs. not reached for patients 50 years of age; P < .001). Despite the fact that 33% of elderly patients died of causes unrelated to WM, disease-specific survival (DSS) was 72 months for patients > 75 years, 120 months for those > 50-75 years and not reached for patients 50 years (P = .001). International Prognostic Scoring System for WM (IPSSWM) could discriminate 3 risk groups with significantly different OS or DSS. The addition of elevated serum lactate dehydrogenase in the IPSS improved the ability of IPSS to identify a group of patients with a significantly worse outcome (median survival, 55 months).

Notes:

Cited By :12Export Date: 21 February 2017

Website